Market Performance - The medical services sector increased by 1.24% on September 12, with Zhaoyan New Drug leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Top Gainers in Medical Services - Zhaoyan New Drug (603127) closed at 37.86, up 9.99% with a trading volume of 554,000 shares [1] - BGI Genomics (300676) closed at 55.81, up 7.58% with a trading volume of 225,300 shares [1] - Haoyuan Pharmaceutical (688131) closed at 74.67, up 6.05% with a trading volume of 69,800 shares [1] Decliners in Medical Services - Yuaner Eye Hospital (300015) closed at 12.97, down 1.14% with a trading volume of 741,800 shares [2] - Nomo Gene (688315) closed at 16.49, down 1.08% with a trading volume of 85,800 shares [2] - Haochen Medical (002622) closed at 3.84, down 1.03% with a trading volume of 200,100 shares [2] Capital Flow Analysis - The medical services sector saw a net inflow of 293 million yuan from institutional investors, while retail investors experienced a net outflow of 207 million yuan [2] - Zhaoyan New Drug had a net inflow of 2.20 billion yuan from institutional investors, but a net outflow of 1.47 billion yuan from retail investors [3] Notable Stocks in Capital Flow - HaiTe Bio (300683) had a net inflow of 112 million yuan from institutional investors, with a net outflow of 1.30 billion yuan from retail investors [3] - Innovation Medical (002173) saw a net inflow of 110 million yuan from institutional investors, while retail investors had a net outflow of 1.12 billion yuan [3]

Group 1 - The core viewpoint of the article highlights a rebound in the innovative drug sector, with notable stock performances from companies like Zhaoyan New Drug, which achieved three consecutive trading limits in six days [1] - The National Medical Products Administration (NMPA) has proposed to further optimize the review and approval process for clinical trials of innovative drugs, aiming to complete the review and approval within 30 working days for eligible applications [1] - This new pathway supports key national research and development projects, encourages early global synchronization of research, and facilitates international multi-center clinical trials to address urgent clinical needs and promote the development of the national pharmaceutical industry [1] Group 2 - Companies such as Yuandong Biological and Saily Medical have seen significant stock price increases, with Yuandong Biological rising over 10% and Saily Medical hitting the daily limit [1] - Other companies in the sector, including Warner Pharmaceuticals, Haoyuan Pharmaceutical, and Huahai Pharmaceutical, also experienced notable gains, indicating a broader positive trend in the innovative drug market [1]

Core Viewpoint - The innovative drug concept stocks are experiencing a rebound, with notable increases in share prices for several companies in the sector [1] Company Summaries - Zhaoyan New Drug reached the daily limit increase in stock price [1] - Yuandong Biological saw a rise of over 10% in its stock price [1] - Guangshengtang, Anglikang, and Saily Medical are among the top gainers in terms of stock price increase [1]

Group 1 - The core viewpoint of the news is that Zhaoyan New Drug has seen a significant increase in its stock price, rising by 5.32% to reach 36.25 yuan per share, with a trading volume of 1.357 billion yuan and a turnover rate of 6.15%, resulting in a total market capitalization of 27.169 billion yuan [1] - Zhaoyan New Drug Research Center Co., Ltd. is primarily engaged in non-clinical safety evaluation services for drugs and the sale of preclinical research services and laboratory animals, established on February 25, 1998, and listed on August 25, 2017 [1] Group 2 - According to data from the top ten heavy stocks of funds, Guojin Fund has a significant holding in Zhaoyan New Drug, with the Guojin Xinyi Medical Consumption A fund holding 256,000 shares, accounting for 4.07% of the fund's net value, ranking as the eighth largest heavy stock [2] - The Guojin Xinyi Medical Consumption A fund, established on June 30, 2020, has a latest scale of 32.205 million yuan, with a year-to-date return of 20.05% and a one-year return of 27.2% [2] - The fund manager, Zhang Wang, has been in position for 5 years and 178 days, with the fund's total asset scale at 360 million yuan, achieving the best return of 47.64% and the worst return of -12.63% during his tenure [2]

Core Viewpoint - Zhaoyan New Drug has shown significant stock price growth in 2023, with a year-to-date increase of 111.57% and a recent market capitalization of 26.322 billion yuan [1] Group 1: Stock Performance - As of September 12, Zhaoyan New Drug's stock price reached 35.12 yuan per share, with a trading volume of 7.81 billion yuan and a turnover rate of 3.58% [1] - The stock has experienced a 3.26% increase over the last five trading days, a 6.55% increase over the last 20 days, and an 87.91% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 29 [1] Group 2: Financial Performance - For the first half of 2025, Zhaoyan New Drug reported a revenue of 669 million yuan, a year-on-year decrease of 21.28%, while the net profit attributable to shareholders increased by 135.90% to 60.9324 million yuan [2] - Since its A-share listing, the company has distributed a total of 703 million yuan in dividends, with 356 million yuan distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.59% to 61,200 [2] - The top five circulating shareholders include Huabao Zhongzheng Medical ETF, which increased its holdings by 2.2669 million shares, and Hong Kong Central Clearing Limited, which reduced its holdings by 943,870 shares [3]

9月10日早盘，医疗板块低开后快速回暖，CXO概念强劲反弹，昭衍新药涨停，康龙化成涨超5%，巨 头药明康德涨超2%。 消息面上，Grand View Research预测，全球CXO市场规模有望从2024年的1970亿美元增长至2030年的 2980亿美元，期间年复合增速为7%，略高于同期全球制药市场6%的年复合增速。 从估值来看，医疗ETF（512170）标的指数中证医疗最新PE估值约为36倍，仍低于近10年逾60%时间区 间，配置性价比相对突出。 牛市"高切低"，关注医疗估值洼地。配置工具认准A股最大医疗ETF（512170）及其联接基金 （012323）：聚焦"医疗器械（52%）+医疗服务（40%）"，与AI医疗高相关，覆盖6只CXO龙头股。截 至9月8日，医疗ETF（512170）规模275亿元，同类规模最大；年初以来日均成交6.45亿元，流动性优 秀。 风险提示：医疗 ETF 及其联接基金被动跟踪中证医疗指数，该指数基日为 2004.12.31 ，发布于 2014.10.31 。 中 证 医 疗 指 数 2020 年 至 2024 年 的 分 年 度 业 绩 分 别 为 79.67% 、 -14.7 ...

Core Viewpoint - The innovative drug concept stocks are experiencing significant activity, with notable gains in several companies, indicating a positive trend in the pharmaceutical sector [1] Company Summaries - Zhaoyan New Drug has reached its daily limit increase, reflecting strong investor interest and confidence in its growth potential [1] - MediXis, Kanglong Chemical, Haixiang Pharmaceutical, Kailaiying, and Jiuzhou Pharmaceutical have also seen upward movement in their stock prices, suggesting a broader rally in the innovative drug sector [1]

证券之星消息，9月9日医疗服务板块较上一交易日下跌2.94%，昭衍新药领跌。当日上证指数报收于 3807.29，下跌0.51%。深证成指报收于12510.6，下跌1.23%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出17.25亿元，游资资金净流入4.63亿元，散户资金 净流入12.62亿元。医疗服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | 32.22 | -7.01% | 47.36万 | 15.66亿 | | 688222 | 成都先导 | 25.13 | -6.79% | 25.48万 | 6.60亿 | | 835670 | 数字人 | 17.97 | -6.60% | 9.56万 | 1.76亿 | | 002173 | 创新医疗 | 22.49 | -5.74% | ...

Core Viewpoint - Zhaoyan New Drug (603127) experienced a decline of over 7%, with a current price of 20.98 HKD and a trading volume of 147 million HKD [1] Group 1: Shareholder Reduction Plans - On September 8, Zhaoyan New Drug announced that several executives, including Vice General Manager Sun Yunxia and General Manager Gao Dapeng, plan to reduce their holdings between September 30, 2025, and November 28, 2025, through Shanghai Stock Exchange transactions, with a total reduction not exceeding 84,830 shares, representing 0.1132% of the company's total share capital [1] - Previously, on September 1, the company disclosed that former Vice Chairman Zuo Conglin planned to reduce his holdings from August 19, 2025, to August 29, 2025, with a maximum reduction of 3,524,500 shares, which was 0.4703% of the company's total share capital at that time [2] - As of August 29, 2025, Zuo Conglin had reduced his holdings by 2,264,900 shares through concentrated bidding, completing his reduction plan [2]

Core Viewpoint - Zhaoyan New Drug (06127) experienced a decline of over 7%, closing at HKD 20.98 with a trading volume of HKD 147 million due to insider selling announcements [1] Group 1: Insider Selling Announcements - On September 8, Zhaoyan New Drug announced that several executives, including Vice General Manager Sun Yunxia and General Manager Gao Dapeng, plan to reduce their holdings between September 30, 2025, and November 28, 2025, through block trades or centralized bidding on the Shanghai Stock Exchange, with a total reduction not exceeding 84,830 shares, representing 0.1132% of the company's total share capital [1] - The planned reductions include 674,700 shares from Sun Yunxia, 72,100 shares from Gao Dapeng, and 67,400 shares from Gu Jingliang, along with additional reductions from supervisor Li Ye and CFO Yu Aishui [1] Group 2: Previous Insider Selling - On September 1, Zhaoyan New Drug disclosed that former Vice Chairman Zuo Conglin had a reduction plan announced on August 14, 2025, intending to sell up to 3,524,500 shares between August 19, 2025, and August 29, 2025, which would account for 0.4703% of the company's total share capital at that time [2] - By August 29, 2025, Zuo Conglin had successfully reduced his holdings by 2,264,900 shares through centralized bidding [2]